™Your Policy Risk Impact Agent
33 chapters · 625 sections in this title.
RCW 69.77.010 Findings—Intent.
1.3K chars
The legislature finds that the process for approval of investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over time, but the process often takes many years. Patie…
RCW 69.77.020 Definitions.
1.7K chars
The definitions in this section apply throughout this chapter unless the context clearly requires otherwise. (1) "Eligible patient" means an individual who meets the requirements of RCW 69.77.040. (2) "Health care facility" means a clinic, nursing home, laboratory, office, or sim…
RCW 69.77.030 Eligible patient and treating physician may request investigational product—Manufacturer may make for treatment—Agreement.
0.9K chars
(1) An eligible patient and his or her treating physician may request that a manufacturer make an investigational product available for treatment of the patient. The request must include a copy of the written informed consent form described in RCW 69.77.050 and an explanation of …
RCW 69.77.040 Patient eligibility for access and treatment with investigational product.
1.5K chars
A patient is eligible to request access to and be treated with an investigational product if: (1) The patient is eighteen years of age or older; (2) The patient is a resident of this state; (3) The patient's treating physician attests to the fact that the patient has a serious or…
